florquinitau F18, JNJ-64042056, JNJ-64042056
64042056ALZ2001
Phase 2 small_molecule active
Quick answer
florquinitau F18, JNJ-64042056, JNJ-64042056 for Preclinical Alzheimer’s Disease is a Phase 2 program (small_molecule) at Janssen-Cilag International N.V. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Janssen-Cilag International N.V.
- Indication
- Preclinical Alzheimer’s Disease
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active